We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

73 hedge funds and large institutions have $102M invested in Palvella Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 29 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $82.2M → $102M (+$19.8M)

14% more call options, than puts

Call options by funds: $2.1M | Put options by funds: $1.84M

0.19% less ownership

Funds ownership: 0.72% → 0.53% (-0.19%)

10% less funds holding

Funds holding: 81 → 73 (-8)

26% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 31

62% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 29

Holders
73
Holders Change
-8
Holders Change %
-9.88%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
11
Reduced
29
Closed
31
Calls
$2.1M
Puts
$1.84M
Net Calls
+$264K
Net Calls Change
+$209K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$8.09M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.74M
3
Citadel Advisors
Citadel Advisors
Florida
+$2.54M
4
Morgan Stanley
Morgan Stanley
New York
+$2.35M
5
PIM
Platinum Investment Management
Australia
+$1.8M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.52M
2
CS
Candriam SCA
Luxembourg
-$3.32M
3
TCM
Tekla Capital Management
Massachusetts
-$2.63M
4
State Street
State Street
Massachusetts
-$2.05M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
51
Cutler Group
California
$49K +$22.6K +103 +178%
SWP
52
Stratos Wealth Partners
Ohio
$48K +$34.2K +156 New
OC
53
Oppenheimer & Co
New York
$47K -$18.6K -85 -36%
TRCT
54
Tower Research Capital (TRC)
New York
$44K +$1.1K +5 +4%
YIH
55
Y-Intercept (HK)
Hong Kong
$42K +$29.8K +136 New
SSA
56
Schonfeld Strategic Advisors
New York
$42K +$30K +137 New
AGM
57
Alpine Global Management
New York
$41K +$29.6K +135 New
US Bancorp
58
US Bancorp
Minnesota
$39K – – –
Baird Financial Group
59
Baird Financial Group
Wisconsin
$38K +$27.4K +125 New
NFSG
60
Newbridge Financial Services Group
Florida
$31K – – –
Barclays
61
Barclays
United Kingdom
$24K -$104K -474 -85%
Wells Fargo
62
Wells Fargo
California
$23K -$1.23M -5,601 -99%
LC
63
Lindbrook Capital
California
$23K -$11K -50 -40%
SWM
64
Spire Wealth Management
Virginia
$19K +$13.8K +63 New
Legal & General Group
65
Legal & General Group
United Kingdom
$8K -$9.21K -42 -61%
Osaic Holdings
66
Osaic Holdings
Arizona
$8K +$5.48K +25 New
VRM
67
Vectors Research Management
New York
$8K +$5.48K +25 New
TC
68
Truvestments Capital
Florida
$5K – – –
BNP Paribas Financial Markets
69
BNP Paribas Financial Markets
France
$4.16K -$17.3K -79 -85%
UBS Group
70
UBS Group
Switzerland
$4K -$156K -710 -98%
CAPTRUST Financial Advisors
71
CAPTRUST Financial Advisors
North Carolina
$4K – – –
FF
72
FourThought Financial
Florida
$3K – – –
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$2K -$104K -475 -99%
TCM
74
Tekla Capital Management
Massachusetts
– -$2.63M -12,792 Closed
SFM
75
Sphera Funds Management
Israel
– -$1.67M -8,125 Closed
1 2
3
4 5

PVLA Hedge Fund Activity: Q2 2021 in Review

73 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2021, worth a combined $102M — up 24% from $82.2M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of PVLA and 23 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $8.09M. The largest seller was BlackRock, cutting an estimated $6.52M.

  • 73 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2021, down from 81 in Q1 2021.
  • Funds reported $102M of Palvella Therapeutics stock for Q2 2021, up 24% quarter-over-quarter.
  • 23 funds opened new Palvella Therapeutics positions in Q2 2021 and 31 closed out, a net change of -8 holders.
  • The largest Palvella Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $8.09M added.
  • The largest Palvella Therapeutics seller in Q2 2021 was BlackRock, an estimated $6.52M sold.

Based on aggregated 13F filings for Q2 2021.